BA
CSTL icon

Bridgewater Associates’s Castle Biosciences CSTL Stock Holding History

Bridgewater Associates’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-29,167
Closed -$687K – 760
2022
Q4 		$687K Sell
29,167
-8,554
-23% -$198K ﹤0.01% 686
2022
Q3 		$984K Buy
37,721
+1,245
+3% +$34.9K 0.01% 701
2022
Q2 		$801K Buy
36,476
+4,373
+14% +$102K ﹤0.01% 831
2022
Q1 		$1.44M Buy
32,103
+7,679
+31% +$317K 0.01% 748
2021
Q4 		$1.05M Sell
24,424
-46
-0.2% -$2.4K 0.01% 565
2021
Q3 		$1.63M Sell
24,470
-1,508
-6% -$106K 0.01% 464
2021
Q2 		$1.91M Buy
+25,978
New +$1.72M 0.01% 498

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Bridgewater Associates's CSTL Position: Q1 2023 in Review

Bridgewater Associates sold out of Castle Biosciences (CSTL) in Q1 2023, closing a stake of 29,167 shares — an estimated $687K sold.

Bridgewater Associates first reported a position in CSTL in Q2 2021 and held it in 7 quarters. The position peaked at $1.91M in Q2 2021. 148 funds tracked by Wall St. Rank hold CSTL as of Q1 2023.

  • Bridgewater Associates reported no remaining Castle Biosciences position as of Q1 2023 after selling out during the quarter.
  • Bridgewater Associates sold 29,167 Castle Biosciences shares in Q1 2023, an estimated $687K.
  • Bridgewater Associates first reported a position in Castle Biosciences in Q2 2021 and held it in 7 quarters.
  • Bridgewater Associates's Castle Biosciences position peaked at $1.91M in Q2 2021.
  • 148 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2023.

Based on Bridgewater Associates's 13F filing for Q1 2023, filed 12 May 2023.